Travere Therapeutics, Inc. (TVTX) Monday said it has submitted supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) seeking full approval of Filspari for the treatment of IgA nephropathy (IgAN), a chronic kidney disease.
In February last year, the FDA had granted accelerated approval to Filspari to reduce protein in the urine (proteinuria) in adults with IgAN.
Phase 3 PROTECT Study had shown that Filspari demonstrated long-term kidney function preservation and achieved a significant reduction in proteinuria versus an active comparator.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.